
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will expand development of its investigational therapy QTORINâ„¢ 3.9% rapamycin anhydrous gel into clinically significant angiokeratomas, a rare and debilitating …
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas Read More